BEIJING, August 6, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the second quarter of 2014.
Second Quarter 2014 Financial Highlights
Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, "We are pleased to report another healthy quarter, with sales and net income both achieving double-digit growth. During the quarter, market demand for plasma products remained strong and we continued to make progress with our penetration into first-tier markets. Guizhou Taibang has resumed production which we believe will contribute to increased sales of plasma-based products in the second half of the year."
Mr. Gao continued, "We are encouraged by our outlook for the remainder of the year. First, we expect the growth momentum we experienced in the first half of 2014 to continue in the second half. Second, Chinese authorities recently issued a notice to reduce the value added tax ("VAT") rate on a wide range of products, effective July 1, 2014. We believe the reduction in the VAT rate from 6% to 3% will have a favorable impact on the sales of all plasma-based products in the second half. We also expect our plasma utilization efficiency to further improve in the second half of the year with the expected launch of our human prothrombin complex concentrate ("PCC") products in the fourth quarter of 2014."
"Finally, we are pleased to announce the completion of our follow-on offering which raised net proceeds of approximately $33.2 million for our Company. Through this transaction, we further broadened our shareholder base and improved liquidity in our stock. We are encouraged with our opportunities for continued growth as we move forward," concluded Mr. Gao.
Second Quarter 2014 Financial Performance
Total sales in the second quarter of 2014 were $60.1 million, an increase of 12.1% from $53.6 million in the same quarter of 2013. Excluding foreign exchange translation effect, the increase in sales was primarily attributable to the volume increases in certain plasma-based products and placenta polypeptide product.
During the second quarter of 2014, human albumin products and IVIG products remained the largest two sales contributors. The average price for both products declined 1.4% and 2.7% respectively, during the quarter, mainly as a result of the Company's efforts to increase the market share of human albumin products and IVIG products in tier one cities through distributors by lowering sales prices.
Cost of sales was $18.9 million in the second quarter of 2014 compared to $16.1 million in the same quarter of 2013. As a percentage of total sales, cost of sales was 31.5%, as compared to 30.1% in the same quarter of 2013. The increase in cost of sales was largely in line with the increases in sales volume and plasma collection costs.
Gross profit increased by 9.9% to $41.2 million in the second quarter of 2014 from $37.5 million in the same quarter of 2013. Gross margin was 68.5% and 69.9% for the three months ended June 30, 2014 and 2013, respectively.
Total operating expenses in the second quarter of 2014 increased slightly by 1.7% to $12.3 million from $12.1 million in the same quarter of 2013. As a percentage of total sales, total operating expenses decreased to 20.4% in the second quarter of 2014 from 22.7% in the same quarter of 2013.
Selling expenses in the second quarter of 2014 increased by 37.5% to $3.3 million from $2.4 million in the same quarter of 2013. As a percentage of total sales, selling expenses were 5.5%, up from 4.6% in the same quarter of 2013. Volume and percentage increases in selling expenses were primarily due to increased sales of placenta polypeptide products. Compared with other products, placenta polypeptide has a relatively higher per unit selling expenses.
General and administrative expenses in the second quarter of 2014 decreased by 20.2% to $7.1 million from $8.9 million in the same quarter of 2013. As a percentage of total sales, general and administrative expenses were 11.8% and 16.5% in the second quarter of 2014 and 2013, respectively. The decrease in general and administrative expenses was mainly due to a decrease in legal expenses. During the second quarter of 2013, the Company incurred legal expenses in relation to the take-over defense against a direct competitor in China. In addition, the Company incurred amortization expenses in the three months ended June 30, 2013 with respect to the GMP certificates and certain other intangible assets which were part of the acquisition of Guizhou Taibang in 2008. Because such intangible assets had been fully amortized by the end of 2013, the Company did not incur corresponding expenses in the three months ended June 30, 2014.
Research and development expenses in the second quarter of 2014 were $1.8 million, compared to $0.8 million in the same quarter of 2013. As a percentage of total sales, research and development expenses for the three months ended June 30, 2014 and 2013 were 3.1% and 1.6%, respectively. The increase in research and development expenses was primarily due to the expenditure paid for certain clinical trial programs and the engagement of external experts for select pipeline products.
Income from operations for the three months ended June 30, 2014 was $28.9 million, an increase of 14.2% from $25.3 million in the same period of 2013. Operating margin increased to 48.1% in the reporting quarter from 47.2% in the same quarter of 2013.
Income tax expense in the second quarter of 2014 was $4.5 million, as compared to $3.7 million in the same quarter of 2013, representing an increase of 21.6%. The effective income tax rates were 14.4% and 14.0% for the three months ended June 30, 2014 and 2013, respectively.
Net income attributable to the Company increased by 21.6% to $19.7 million in the second quarter of 2014, from $16.2 million in the same quarter of 2013. Net margins were 32.8% and 30.2% for the three months ended June 30, 2014 and 2013, respectively. Fully diluted net income per share was $0.79 in the second quarter of 2014, as compared to $0.57 in the second quarter of 2013.
Non-GAAP adjusted net income attributable to the Company was $20.5 million or $0.82 per diluted share in the second quarter of 2014, compared to $17.4 million or $0.62 per diluted share in the same quarter of 2013.
Non-GAAP adjusted net income and diluted earnings per share for the three months ended June 30, 2014 excluded $0.8 million of non-cash employee share-based compensation expenses.
First Half 2014 Financial Performances
Total sales in the first half of 2014 were $116.3 million, an increase of 8.1% from $107.6 million in the same period of 2013. The increase in sales was primarily driven by increased sales at Shandong Taibang during the first half of 2014, partially offset by reduced sales volume at Guizhou Taibang in the period due to production suspension. The increased sales volume of placenta polypeptide products also contributed to the sales increase.
As a percentage of total sales, sales from human albumin products and IVIG products were 38.1% and 40.4%, respectively, for the six months ended June 30, 2014.
Cost of sales increased by 11.9% to $36.6 million in the first half of 2014, from $32.7 million in the same period of 2013. Cost of sales as a percentage of total sales was 31.5%, as compared to 30.4% in the same period of 2013.
Gross profit increased by 6.4% to $79.7 million in the first half of 2014 from $74.9 million in the same period of 2013. Gross margin was 68.5% in the first half of 2014, compared to 69.6% in the same period of 2013.
Total operating expenses in the first half of 2014 decreased by 3.0% to $22.9 million from $23.6 million in the same period of 2013. The decrease of total operating expenses was a combined effect of the decrease in the general and administrative expenses and the increase in the selling expenses and research and development expenses. As a percentage of total sales, total operating expenses decreased to 19.6% for the six months ended June 30, 2014, from 21.9% in the same period of 2013.
Income from operations for the six months ended June 30, 2014 was $56.9 million, an increase of 10.9% from $51.3 million in the same period of 2013.
Income tax expense in the first half of 2014 was $9.8 million, as compared to $8.4 million in the same period of 2013. The effective income tax rates were 16.2% and 15.7% for the six months ended June 30, 2014 and 2013, respectively. The tax rate applicable to the Company's major operating subsidiaries in the PRC for 2014 and 2013 is 15%.
Net income attributable to the Company increased by 22.2% to $38.0 million for the six months ended June 30, 2014, from $31.1 million in the same period of 2013. Net margins were 32.7% and 28.9% for the six months ended June 30, 2014 and 2013, respectively.
Non-GAAP adjusted net income attributable to the Company was $39.6 million or $1.53 per diluted share for the six months ended June 30, 2014 compared with $33.8 million or $1.21 per diluted share in the same period of 2013.
Non-GAAP adjusted net income and diluted earnings per share in the six months ended June 30, 2014 excluded $1.6 million of non-cash employee share-based compensation expenses.
As of June 30, 2014, the Company had cash and cash equivalents of $103.2 million, compared to $144.1 million as of December 31, 2013. Restricted deposits were $102.1 million as of June 30, 2014, compared to $30.5 as of December 31, 2013. The increase was primarily due to a deposit of $72.3 million as cash collateral for certain long-term bank loans in connection with a payment of $70.0 million for share repurchase. Net cash provided by operating activities for the six months ended June 30, 2014 was $39.0 million, as compared to $37.9 million for the six months ended June 30, 2013. The increase in net cash provided by operating activities was primarily due to the increase in net income for the six months ended June 30, 2014 as compared to the same period in 2013, partially offset by the increase of accounts receivable and the inventories during this period. Accounts receivable increased by $7.5 million, in line with the sales increase during the six months ended June 30, 2014, as compared to $6.3 million during the same period in 2013. Inventories increased by $6.9 million during the six months ended June 30, 2014, as compared to $3.6 million during the same period in 2013. This increase was primarily due to an increase in raw materials as a result of the continued supply of plasma, a primary raw material, by plasma stations of Guizhou Taibang while its production of plasma products had been suspended from June 2013 to March 2014.
Outlook
For the full year of 2014, the Company reiterates its full year financial forecast of total sales in the range of $230 million to $240 million and full year non-GAAP adjusted net income in the range of $67 million to $69 million. This guidance assumes only organic growth and excludes acquisitions and necessarily assumes no significant adverse product price changes during 2014.
This forecast reflects the Company's current and preliminary views, which are subject to change.
Conference Call
The Company will host a conference call at 8:00 am, Eastern Time on Wednesday, August 6, 2014, which is 8:00 pm, Beijing Time on August 6, 2014, to discuss second quarter 2014 results and answer questions from investors. Listeners may access the call by dialing:
US: | +1 877 870 4263 |
International: | +1 412 317 0790 |
Hong Kong: | 800 905 945 |
Mainland China: | 400 120 1203 |
Passcode: | China Biologic Products Inc. |
A telephone replay will be available one hour after the conclusion of the conference all through 9:00 am, Eastern Time on August 13, 2014. The dial-in details are:
US: | +1 877 344 7529 |
International: | +1 412 317 0088 |
Passcode: | 10050434 |
A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com.
About China Biologic Products, Inc.
China Biologic is a leading plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and inoculation centers, as well as distributors, in China. For additional information, please see the Company's website www.chinabiologic.com.
Non-GAAP Disclosure
This news release contains non-GAAP financial measures that exclude non-cash compensation expenses related to options granted to employees and directors under the Company's 2008 Equity Incentive Plan. To supplement the Company's unaudited condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of these items in this release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of the adjustments to GAAP results appears in the table accompanying this news release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.
Safe Harbor Statement
This news release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.
Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including its potential inability to achieve the expected operating and financial performance in 2014, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Contact:
China Biologic Products, Inc.
Mr. Ming Yin
Senior Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com
ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: bill.zima@icrinc.com
Financial statements follow.
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES | ||||||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | ||||||||||
For the three months ended | For the six months ended | |||||||||
June 30, | June 30, | June 30, | June 30, | |||||||
2014 | 2013 | 2014 | 2013 | |||||||
USD | USD | USD | USD | |||||||
Sales | 60,073,984 | 53,580,523 | 116,340,561 | 107,612,255 | ||||||
Cost of sales | 18,919,981 | 16,122,262 | 36,635,147 | 32,739,020 | ||||||
Gross profit | 41,154,003 | 37,458,261 | 79,705,414 | 74,873,235 | ||||||
Operating expenses | ||||||||||
Selling expenses | 3,329,175 | 2,441,727 | 5,611,661 | 4,278,120 | ||||||
General and administrative expenses | 7,112,798 | 8,866,071 | 14,329,424 | 17,553,168 | ||||||
Research and development expenses | 1,838,795 | 835,150 | 2,912,361 | 1,748,242 | ||||||
Income from operations | 28,873,235 | 25,315,313 | 56,851,968 | 51,293,705 | ||||||
Other income (expenses) | ||||||||||
Equity in income of an equity method investee | 1,523,216 | 610,997 | 1,860,579 | 739,945 | ||||||
Interest expense | (862,957) | (198,739) | (1,484,164) | (434,913) | ||||||
Interest income | 1,724,324 | 995,757 | 3,320,202 | 1,643,819 | ||||||
Total other income, net | 2,384,583 | 1,408,015 | 3,696,617 | 1,948,851 | ||||||
Earnings before income tax expense | 31,257,818 | 26,723,328 | 60,548,585 | 53,242,556 | ||||||
Income tax expense | 4,486,157 | 3,745,649 | 9,824,375 | 8,352,551 | ||||||
Net income | 26,771,661 | 22,977,679 | 50,724,210 | 44,890,005 | ||||||
Less: Net income attributable to noncontrolling interest | 7,046,706 | 6,815,753 | 12,725,584 | 13,812,219 | ||||||
Net income attributable to China Biologic Products, Inc. | 19,724,955 | 16,161,926 | 37,998,626 | 31,077,786 | ||||||
Net income per share of common stock: | ||||||||||
Basic | 0.83 | 0.60 | 1.55 | 1.15 | ||||||
Diluted | 0.79 | 0.57 | 1.47 | 1.11 | ||||||
Weighted average shares used in computation: | ||||||||||
Basic | 23,483,090 | 26,880,459 | 24,212,766 | 26,833,262 | ||||||
Diluted | 24,719,011 | 28,067,303 | 25,435,122 | 27,967,080 | ||||||
Net income | 26,771,661 | 22,977,679 | 50,724,210 | 44,890,005 | ||||||
Other comprehensive income : | ||||||||||
Foreign currency translation adjustment, net of nil income taxes | 527,203 | 4,428,715 | (2,589,440) | 5,825,256 | ||||||
Comprehensive income | 27,298,864 | 27,406,394 | 48,134,770 | 50,715,261 | ||||||
Less: Comprehensive income attributable to noncontrolling interest | 7,140,585 | 7,723,790 | 12,245,986 | 14,882,947 | ||||||
Comprehensive income attributable to China Biologic Products, Inc. | 20,158,279 | 19,682,604 | 35,888,784 | 35,832,314 | ||||||
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES | |||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
June 30, | December 31, | ||||
2014 | 2013 | ||||
USD | USD | ||||
ASSETS | |||||
Current Assets | |||||
Cash and cash equivalents | 103,223,625 | 144,138,487 | |||
Time deposit | - | 6,608,612 | |||
Restricted deposits | 30,387,500 | - | |||
Accounts receivable, net of allowance for doubtful accounts | 24,598,123 | 17,270,132 | |||
Inventories | 94,812,741 | 88,634,855 | |||
Prepayments and other current assets | 8,962,789 | 7,641,061 | |||
Total Current Assets | 261,984,778 | 264,293,147 | |||
Property, plant and equipment, net | 76,966,843 | 73,149,072 | |||
Land use rights, net | 9,407,386 | 8,213,145 | |||
Deposits related to land use rights | 11,941,943 | 13,667,130 | |||
Restricted cash and deposits, excluding current portion | 71,753,816 | 30,523,674 | |||
Equity method investment | 13,127,429 | 11,349,807 | |||
Other non-current assets | 4,271,138 | 2,585,232 | |||
Total Assets | 449,453,333 | 403,781,207 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||
Current Liabilities | |||||
Short-term bank loans, including current portion of long-term bank loans | 34,875,000 | 9,822,000 | |||
Accounts payable | 3,975,739 | 4,445,732 | |||
Due to related parties | 6,845,003 | 7,206,970 | |||
Other payables and accrued expenses | 31,224,373 | 34,852,740 | |||
Advance from customers | 4,577,531 | 2,908,853 | |||
Income tax payable | 4,536,159 | 4,202,405 | |||
Total Current Liabilities | 86,033,805 | 63,438,700 | |||
Long-term bank loans, excluding current portion | 70,000,000 | 30,000,000 | |||
Deferred income | 2,907,328 | 3,003,895 | |||
Other liabilities | 4,041,464 | 3,369,003 | |||
Total Liabilities | 162,982,597 | 99,811,598 | |||
Stockholders' Equity | |||||
Common stock: | |||||
par value $0.0001; | |||||
100,000,000 shares authorized; | |||||
27,540,800 and 27,341,744 shares issued at June 30, 2014 and December 31, 2013, respectively; | |||||
23,561,096 and 25,862,040 shares outstanding at June 30, 2014 and December 31, 2013, respectively | 2,754 | 2,734 | |||
Additional paid-in capital | 76,267,027 | 72,031,864 | |||
Treasury stock: 3,979,704 and 1,479,704 shares at June 30, 2014 and December 31, 2013, respectively, at cost | (99,594,080) | (29,594,080) | |||
Retained earnings | 211,743,177 | 173,744,551 | |||
Accumulated other comprehensive income | 19,396,652 | 21,506,494 | |||
Total equity attributable to China Biologic Products, Inc. | 207,815,530 | 237,691,563 | |||
Noncontrolling interest | 78,655,206 | 66,278,046 | |||
Total Stockholders' Equity | 286,470,736 | 303,969,609 | |||
Commitments and contingencies | - | - | |||
Total Liabilities and Stockholders' Equity | 449,453,333 | 403,781,207 | |||
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES | ||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
For the six months ended | ||||||
June 30, | June 30, | |||||
2014 | 2013 | |||||
USD | USD | |||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||
Net income | 50,724,210 | 44,890,005 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||
Depreciation | 3,289,535 | 3,105,739 | ||||
Amortization | 371,168 | 702,556 | ||||
Loss (gain) on sale of property, plant and equipment | 71,494 | (70,363) | ||||
Provision of doubtful accounts, net | 1,477 | - | ||||
Provision of doubtful accounts - other receivables and prepayments | - | 6,202 | ||||
Write-down of obsolete inventories | 9,092 | - | ||||
Deferred tax expense | 1,154,991 | 720,679 | ||||
Share-based compensation | 1,961,929 | 3,047,962 | ||||
Equity in income of an equity method investee | (1,860,579) | (739,945) | ||||
Excess tax benefits from share-based compensation arrangements | (760,869) | - | ||||
Change in operating assets and liabilities: | ||||||
Accounts receivable | (7,473,499) | (6,314,643) | ||||
Prepayment and other assets | (2,393,459) | (101,135) | ||||
Inventories | (6,852,680) | (3,616,165) | ||||
Accounts payable | (438,427) | 242,365 | ||||
Other payables and accrued expenses | (1,287,497) | (2,033,594) | ||||
Advance from customers | 1,693,953 | (529,984) | ||||
Due to related parties | (309,859) | (140,697) | ||||
Income tax payable | 1,126,281 | (1,260,254) | ||||
Net cash provided by operating activities | 39,027,261 | 37,908,728 | ||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||
Payment for property, plant and equipment | (10,243,198) | (11,912,603) | ||||
Payment for intangible assets and land use right | (1,227,914) | (1,137,556) | ||||
Dividend received | - | 560,980 | ||||
Refund of deposits related to land use right | 1,635,200 | - | ||||
Proceeds upon maturity of time deposit | 6,608,612 | - | ||||
Proceeds from sale of property, plant and equipment | 190,660 | 83,731 | ||||
Net cash used in investing activities | (3,036,640) | (12,405,448) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
Proceeds from stock option exercised | 1,643,559 | 2,668,916 | ||||
Proceeds from short term bank loans | - | 4,808,400 | ||||
Repayment of short term bank loans | (4,905,600) | (8,014,000) | ||||
Proceeds from long-term bank loans | 70,000,000 | - | ||||
Payment for deposits as security for long-term bank loans | (72,290,922) | - | ||||
Payment for share repurchase | (70,000,000) | - | ||||
Acquisition of noncontrolling interest | - | (1,963,913) | ||||
Excess tax benefits from share-based compensation arrangements | 760,869 | - | ||||
Dividend paid by subsidiaries to noncontrolling interest shareholders | (1,409,542) | (8,110,168) | ||||
Net cash used in financing activities | (76,201,636) | (10,610,765) | ||||
EFFECTS OF FOREIGN EXCHANGE RATE CHANGE ON CASH | (703,847) | 2,762,616 | ||||
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | (40,914,862) | 17,655,131 | ||||
Cash and cash equivalents at beginning of period | 144,138,487 | 129,609,317 | ||||
Cash and cash equivalents at end of period | 103,223,625 | 147,264,448 | ||||
Supplemental cash flow information | ||||||
Cash paid for income taxes | 7,564,408 | 8,892,126 | ||||
Cash paid for interest expense | 1,067,251 | 198,900 | ||||
Noncash investing and financing activities: | ||||||
Acquisition of property, plant and equipment included in payables | 2,805,220 | 1,554,828 | ||||
Transfer from prepayments to property, plant and equipment | 727,937 | 6,815,689 | ||||
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES | |||||
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | |||||
For the three months ended | |||||
June 30, | June 30, | ||||
2014 | 2013 | ||||
USD | USD | ||||
Adjusted Net Income Attributable to the Company - Non GAAP | 20,522,830 | 17,406,925 | |||
Diluted EPS - Non GAAP | 0.82 | 0.62 | |||
Non-cash employee stock compensation | (797,875) | (1,244,999) | |||
Net Income Attributable to the Company | 19,724,955 | 16,161,926 | |||
Weighted average number of shares used in computation of Non GAAP diluted EPS | 24,719,011 | 28,067,303 | |||
For the six months ended | |||||
June 30, | June 30, | ||||
2014 | 2013 | ||||
USD | USD | ||||
Adjusted Net Income Attributable to the Company - Non GAAP | 39,594,376 | 33,801,545 | |||
Diluted EPS - Non GAAP | 1.53 | 1.21 | |||
Non-cash employee stock compensation | (1,595,750) | (2,723,759) | |||
Net Income Attributable to the Company | 37,998,626 | 31,077,786 | |||
Weighted average number of shares used in computation of Non GAAP diluted EPS | 25,435,122 | 27,967,080 | |||
